NASDAQ$TELA

TELA Bio Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

TELA Bio reported an 11% increase in revenue compared to the same period in 2023, driven by increased unit sales, offset by decreased average selling prices. The company is reiterating its full-year revenue guidance.

TELA Bio reported revenue of $16.1 million for the second quarter of 2024, an 11% increase compared to the same period in 2023. The company is reiterating its 2024 revenue target of $74.5 million to $76.5 million.

  • Revenue increased by 11% to $16.1 million compared to Q2 2023.
  • Gross profit was $11.1 million, representing 69% of revenue.
  • Operating expenses were $22.6 million.
  • Net loss was $12.6 million.

Headline financials

Total Revenue

$16.1M

Previous: $14.5M+11.0%
EPS

-$0.51

Previous: -$0.46-10.9%
Gross Margin

68.8%

No prior period
Capital Expenditures

-$603K

Previous: -$272K-121.7%
Free Cash Flow

-$13.2M

Previous: -$11.1M-19.4%
Net Income

-$12.6M

Previous: -$10.8M-16.8%
Operating Income

-$11.6M

Previous: -$10.4M-11.7%
Gross Profit

$11.1M

Previous: $10.2M+8.5%
Cash & Equivalents

$26.5M

Previous: $65.3M-59.4%
Total Assets

$60.2M

Previous: $94.4M-36.2%
R&D Expense

$2.32M

No prior period
Stock-Based Comp

$1.09M

Previous: $1.29M-15.8%

Revenue & EPS history

TELA Bio · Revenue · Quarterly

$16.1M

Q2 2024+11%vs Q2 2023
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Forward guidance

TELA Bio is reiterating its 2024 revenue target of $74.5 million to $76.5 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

-2.5%

Avg return

Earnings day

-3.0%

Avg return

5 days after

+3.5%

Avg return

30 days after

42%

11 / 26 earnings

Positive

+20.2%

Q1 2024

Best reaction

-37.2%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+1.7%-9.3%
Q1 2026-5.3%-18.6%-15.7%
Q3 2025-9.3%-2.7%+3.6%
Q1 2025+7.2%-0.1%+90.7%
Q4 2024-37.2%-44.9%-59.1%
Q3 2024+2.0%+3.0%-1.7%
Q2 2024-23.9%-23.4%-35.0%
Q1 2024+20.2%+21.2%+16.7%
Q4 2023+4.0%+0.9%-13.8%
Q3 2023-20.3%-21.7%-4.5%
Q2 2023-4.8%-1.2%-2.8%
Q1 2023-3.6%-4.8%+11.2%
Q4 2022-5.5%-3.7%-11.3%
Q3 2022+13.8%+11.2%+44.7%
Q2 2022-6.5%+5.5%+0.9%
Q1 2022-5.7%-7.0%-31.4%
Q4 2021-4.8%-4.8%-20.4%
Q3 2021-3.8%-3.7%-1.7%
Q2 2021+5.0%+4.4%-8.3%
Q1 2021+3.2%+11.5%+5.9%
Q4 2020-6.6%+0.9%-1.8%
Q3 2020-3.5%-0.8%-3.6%
Q2 2020+5.4%+4.1%+20.7%
Q1 2020-2.4%-3.6%+38.6%
Q4 2019+0.6%-0.4%+34.0%
Q3 2019+13.9%+8.8%+32.6%
Q2 2019
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro